{
    "organizations": [],
    "uuid": "d518e54400a9d283bb1e798426271a260f8636b7",
    "author": "",
    "url": "https://www.reuters.com/article/brief-bristol-myers-says-opdivo-demonstr/brief-bristol-myers-says-opdivo-demonstrated-sustained-overall-survival-advantage-over-standard-of-care-in-patients-with-recurrent-or-metastatic-squamous-cell-carcinoma-of-the-head-and-neck-idUSFWN1RT0T2",
    "ord_in_thread": 0,
    "title": "BRIEF-Bristol-Myers Says Opdivo Demonstrated Sustained Overall Survival Advantage Over Standard Of Care In Patients With Recurrent Or Metastatic Squamous Cell Carcinoma Of The Head And Neck",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Market News April 16, 2018 / 8:17 PM / Updated 6 minutes ago BRIEF-Bristol-Myers Says Opdivo Demonstrated Sustained Overall Survival Advantage Over Standard Of Care In Patients With Recurrent Or Metastatic Squamous Cell Carcinoma Of The Head And Neck Reuters Staff 1 Min Read \nApril 16 (Reuters) - Bristol-Myers Squibb Co: \n* IN CHECKMATE -141, OPDIVO (NIVOLUMAB) DEMONSTRATED SUSTAINED OVERALL SURVIVAL (OS) ADVANTAGE OVER STANDARD OF CARE IN PATIENTS WITH RECURRENT OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN) \n* BRISTOL-MYERS SQUIBB CO - PATIENTS TREATED WITH OPDIVO EXPERIENCED A 32% REDUCTION IN RISK OF DEATH AFTER TWO YEARS MINIMUM FOLLOW-UP \n* BRISTOL-MYERS SQUIBB CO - SAFETY PROFILE FOR OPDIVO AT TWO-YEAR FOLLOW-UP WAS CONSISTENT WITH PREVIOUS ANALYSES FROM STUDY \n* BRISTOL-MYERS SQUIBB CO - IN STUDY, TWO-YEAR SURVIVAL RATE FOR OPDIVO WAS 16.9% VERSUS 6.0% FOR STANDARD CHEMOTHERAPY \n* BRISTOL-MYERS SQUIBB CO - THERE WERE NO STATISTICALLY SIGNIFICANT DIFFERENCES BETWEEN 2 ARMS FOR PFS FOR OPDIVO & INVESTIGATORâ€™S CHOICE, RESPECTIVELY \n* BRISTOL-MYERS SQUIBB CO - SAFETY PROFILE OF OPDIVO WITH A TWO-YEAR FOLLOW-UP WAS CONSISTENT WITH PREVIOUS ANALYSES Source text for Eikon: Further company coverage:",
    "published": "2018-04-16T23:13:00.000+03:00",
    "crawled": "2018-04-16T23:31:40.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "market",
        "news",
        "april",
        "pm",
        "updated",
        "minute",
        "ago",
        "say",
        "opdivo",
        "demonstrated",
        "sustained",
        "overall",
        "survival",
        "advantage",
        "standard",
        "care",
        "patient",
        "recurrent",
        "metastatic",
        "squamous",
        "cell",
        "carcinoma",
        "head",
        "neck",
        "reuters",
        "staff",
        "min",
        "read",
        "april",
        "reuters",
        "squibb",
        "co",
        "checkmate",
        "opdivo",
        "nivolumab",
        "demonstrated",
        "sustained",
        "overall",
        "survival",
        "o",
        "advantage",
        "standard",
        "care",
        "patient",
        "recurrent",
        "metastatic",
        "squamous",
        "cell",
        "carcinoma",
        "head",
        "neck",
        "scchn",
        "squibb",
        "co",
        "patient",
        "treated",
        "opdivo",
        "experienced",
        "reduction",
        "risk",
        "death",
        "two",
        "year",
        "minimum",
        "squibb",
        "co",
        "safety",
        "profile",
        "opdivo",
        "consistent",
        "previous",
        "analysis",
        "study",
        "squibb",
        "co",
        "study",
        "survival",
        "rate",
        "opdivo",
        "versus",
        "standard",
        "chemotherapy",
        "squibb",
        "co",
        "statistically",
        "significant",
        "difference",
        "arm",
        "pfs",
        "opdivo",
        "investigator",
        "choice",
        "respectively",
        "squibb",
        "co",
        "safety",
        "profile",
        "opdivo",
        "consistent",
        "previous",
        "analysis",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}